MAR 0 A			U.S. Patents are required to respond to a collection Application Number Filing Date First Named Inventor Art Unit Examiner Name	Approved for use through 04/30/2003. OMB 0651-003 ant and Trademark Office; U.S. DEPARTMENT OF COMMERCI ion of information unless it displays a valid OMB control number 10/051,819 January 14, 2002 Besterman 1644 NA
<u> </u>	Total Number of Pages in This Submission	4 "	Attorney Docket Number	MET-002US1
· [Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	F F F F F F F F F F F F F F F F F F F	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addra Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
0	Firm Wayne A. Keown, Ph.D. (R		OF APPLICANT, ATTORN 33,923)	EY, OR AGENT
	Individual Signature			

CERTIFICATE OF TRANSMISSION/MAILING									
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:									
Typed or printed	laura	Labrer							
Signature	Lausa	Sallie	Date	2/27/03					

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



IN THE UNIAND STATES PATENT AND TRADEMARK OFFICE

OIPE JOIN	$\mathbf{A}_{\mathbf{j}}$
•	Se
MAR 0 4 2003	Fi
TRADEMARK.	Tr.

Besten, n et al.

erial No.: 10/051,81

Examiner: NA

Filed:

January 14, _002

Group Art Unit: 1644

Entitled:

METHODS FOR INHIBITING HISTONE

DEACETYLASE-4

Attorney Docket No.:

MET-002US1 (1002/003)

Assistant Commissioner for Patents Washington, DC 20231

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt for the above-identified application. Please note the misspelling of the name Zuomei Li.

The attached Filing Receipt shows the corrections marked in red ink for your convenience. Please issue a new Corrected Filing Receipt.

Respectfully submitted,

Ey:

Wayne A. Keown, Ph.D.

Reg. No. 33,923

Date

Pr. A appaint to a

Keown & Associates 500 West Cummings Park

Suite 1200

Woburn, MA 01801

781-938-1805

781-938-4777 (Fax)






Commissioner for Patents Washington, DC 20231 www.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 10/051,819
 01/14/2002
 1644
 1517
 MET-002 (1002/003)
 7
 91
 7

32254 KEOWN & ASSOCIATES 500 WEST CUMMINGS PARK SUITE 1200 WOBURN, MA 01801



CONFIRMATION NO. 6029
UPDATED FILING RECEIPT

OC000000009509840

Date Mailed: 02/12/2003

"Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filling Receipt, please write to the Office of Initial Patent Examination's Filling Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Zuomei Li

Jeffrey M. Besterman, Baie D' Urfe, CANADA; Claire Bonfils, Montreal, CANADA; Li-Zuomei, Kirkland, CANADA; Soon Hyung Woo, Beaconsfield, CANADA; Arkadii Vaisburg, Kirkland, CANADA; Daniel Delorme, St-Lazare, CANADA; Marielle Fournel, La Salle, CANADA; Rico Lavoie, Hemden, CT;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/261,674 01/12/2001

Foreign Applications

If Required, Foreign Filing License Granted: 03/14/2002

Projected Publication Date: 05/22/2003

Non-Publication Request: No

Early Publication Request: No



Title

Methods for inhibiting histone deacetylase-4

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).